NCCN-IPI for Diffuse Large B-Cell Lymphoma
Refined prognostic index for DLBCL treated with R-CHOP — more discriminating than original IPI for older and younger patients.
Score interpretation
NCCN-IPI 0–1: 5-year OS ~96%.
→ Standard R-CHOP. Excellent prognosis.
NCCN-IPI 2–3: 5-year OS ~82%.
→ Standard R-CHOP. Good prognosis. Consider clinical trial if available.
NCCN-IPI 4–5: 5-year OS ~64%.
→ Discuss clinical trial enrolment. Consider intensified therapy or CNS prophylaxis as appropriate.
NCCN-IPI ≥ 6: 5-year OS ~33%.
→ Intensified or novel therapy regimens. Clinical trial enrolment recommended. CNS prophylaxis. Early discussion of consolidation with autologous SCT.
Interpretation bands for the NCCN-IPI. Apply clinical judgement and local guidance.
References
- Zhou Z et al. Optimizing the Diffuse Large B-Cell Lymphoma Clinical Trial with the National Comprehensive Cancer Network International Prognostic Index. Leuk Lymphoma. 2014;55(10):2218-2227.
Related
Curated clinical cross-links plus same-class fallbacks.
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- Ann Arbor Staging for Lymphoma · Lymphoma
- CNS International Prognostic Index (CNS-IPI) for DLBCL · Lymphoma
- MALT Lymphoma International Prognostic Index (MALT-IPI) · Lymphoma
- Mantle Cell Lymphoma International Prognostic Index (MIPI) · Lymphoma
- R-IPI — Revised International Prognostic Index for DLBCL · Lymphoma
- Sodium Cromoglicate Nasal Spray · Mast Cell Stabiliser — Allergic Rhinitis
- Olopatadine · H1 antihistamine + mast cell stabiliser
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Crizanlizumab · P-selectin Inhibitor — Sickle Cell Disease
- Obinutuzumab · Anti-CD20 Monoclonal Antibody — CLL / Follicular Lymphoma
- Voxelotor · Haemoglobin S Polymerisation Inhibitor — Sickle Cell Disease
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.